Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmInvestors Business Daily • 11/16/22
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatmentsMarket Watch • 11/14/22
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And OthersInvestors Business Daily • 11/14/22
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemabMarket Watch • 11/14/22
Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency DisorderBusiness Wire • 10/31/22
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MSGlobeNewsWire • 10/26/22
New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MSGlobeNewsWire • 10/26/22